Soh S E, Aw M, Gerez I, Chong Y S, Rauff M, Ng Y P M, Wong H B, Pai N, Lee B W, Shek L P-C
Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore and National University Hospital, Singapore.
Clin Exp Allergy. 2009 Apr;39(4):571-8. doi: 10.1111/j.1365-2222.2008.03133.x. Epub 2008 Dec 9.
The role of probiotics in allergy prevention remains uncertain but has been shown in some studies to have a possible protective effect on eczema.
We aimed to assess the effect of probiotic supplementation in the first 6 months of life on eczema and allergic sensitization at 1 year of age in Asian infants at risk of allergic disease.
A double-blind, placebo-controlled randomized clinical trial involving 253 infants with a family history of allergic disease was carried out. Infants received at least 60 mL of commercially available cow's milk formula with or without probiotic supplementation [Bifidobacterium longum (BL999) 1 x 10(7) colony forming unit (CFU)/g and Lactobacillus rhamnosus (LPR) 2 x 10(7) CFU/g] daily for the first 6 months. Clinical evaluation was performed at 1, 3, 6 and 12 months of age, with serum total IgE measurement and skin prick tests conducted at the 12-month visit. The primary and secondary end-points were eczema and allergen sensitization, respectively.
The incidence of eczema in the probiotic (22%) group was similar to that in the placebo group (25%) (P=0.53). The median Scoring Atopic Dermatitis score at 12 months was 17.10 (9.74) in the probiotic group and 11.60 (8.40) in the placebo group (P=0.17). The prevalence of allergen sensitization showed no difference (probiotic=24% vs. placebo=19%, P=0.26). The total IgE geometric mean (95% confidence interval) was 18.76 (12.54-24.98) kU/L in the probiotic group and 23.13 (16.01-30.24) kU/L in the placebo group (P=0.15). Atopic eczema (with sensitization) in the probiotic (7.3%) group was comparable to the placebo group (5.8%) (P=0.86).
Early life administration of a cow's milk formula supplemented with probiotics showed no effect on prevention of eczema or allergen sensitization in the first year of life in Asian infants at risk of allergic disease. Further work is needed to determine whether timing of supplementation, dose and probiotic strain are important considerations.
益生菌在预防过敏方面的作用仍不确定,但一些研究表明其对湿疹可能具有保护作用。
我们旨在评估在出生后前6个月补充益生菌对有过敏疾病风险的亚洲婴儿1岁时湿疹和过敏致敏的影响。
开展了一项双盲、安慰剂对照的随机临床试验,纳入253名有过敏疾病家族史的婴儿。婴儿在出生后的前6个月每天接受至少60毫升市售牛奶配方奶,其中一部分添加益生菌[长双歧杆菌(BL999)1×10⁷菌落形成单位(CFU)/克和鼠李糖乳杆菌(LPR)2×10⁷CFU/克],另一部分不添加。在1、3、6和12月龄时进行临床评估,在12月龄访视时进行血清总IgE测量和皮肤点刺试验。主要终点和次要终点分别为湿疹和过敏原致敏。
益生菌组(22%)的湿疹发病率与安慰剂组(25%)相似(P = 0.53)。益生菌组12月龄时特应性皮炎评分中位数为17.10(9.74),安慰剂组为11.60(8.40)(P = 0.17)。过敏原致敏率无差异(益生菌组=24%,安慰剂组=19%,P = 0.26)。益生菌组总IgE几何均值(95%置信区间)为18.76(12.54 - 24.98)kU/L,安慰剂组为23.13(16.01 - 30.24)kU/L(P = 0.15)。益生菌组特应性湿疹(伴致敏)发生率(7.3%)与安慰剂组(5.8%)相当(P = 0.86)。
对于有过敏疾病风险的亚洲婴儿,在生命早期给予添加益生菌的牛奶配方奶对预防1岁内的湿疹或过敏原致敏无效果。需要进一步研究来确定补充益生菌的时间、剂量和菌株是否为重要的影响因素。